Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00339066 · ClinicalTrials.gov registry record · NA

Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression

A NA study of Depression, sponsored by Duke University.

Completed
Registry status
NA
Development phase
131
Enrollment target
2
Study locations

NCT00339066 is a NA study of Depression that has completed, run by Duke University. The registered enrollment target is 131 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00339066, a NA study of Depression, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target
2
Study locations

Study Summary

This study will determine the relationship between brain lesion severity, treatment response, and frontal lobe brain function in people with late-life depression (LLD).

Conditions Studied

Depression

Interventions

  • DRUG Sertraline

Study Locations (2)

Missouri

  • Washington University in St. Louis - St Louis

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2001-08
Est. Completion 2006-03
Phase NA

Sponsor

Duke University

1,725 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00339066

The ClinicalTrials.gov registry entry for NCT00339066 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Sertraline is the first listed.

NCT00339066 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00339066 about?

NCT00339066 is a clinical study titled "Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression". This study will determine the relationship between brain lesion severity, treatment response, and frontal lobe brain function in people with late-life depression (LLD).

What is the current status of trial NCT00339066?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2001-08. Estimated completion is 2006-03.

What conditions does trial NCT00339066 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00339066?

The interventions under investigation include: Sertraline (DRUG).

Who is sponsoring clinical trial NCT00339066?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00339066 being conducted?

This trial has 2 study locations across Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depression

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.